v3.26.1
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Net Loss $ 3,265,494 $ 3,377,179 $ 3,933,918 $ 2,834,405 $ 6,642,673 $ 6,768,323
Reportable Segment, Aggregation before Other Operating Segment [Member]            
Segment Reporting [Line Items]            
Preclinical, clinical trial and other costs 326,117   2,142,229   1,749,158 3,339,263
Research and development personnel expense [1] 323,760   305,057   709,883 696,504
General and administrative personnel expense [2] 585,743   628,330   1,262,170 1,302,167
Administrative and facilities expense [3] 1,100,518   875,167   1,946,141 1,459,839
Other expense, net [4] 929,356   (16,865)   975,321 (29,450)
Net Loss $ 3,265,494   $ 3,933,918   $ 6,642,673 $ 6,768,323
[1] Research and development personnel costs include employee stock-based compensation expense of $17,145 and $8,613 for the three months ended June 30, 2026 and 2025, respectively, and $34,289 and $55,333 for the six months ended June 30, 2026 and 2025, respectively.
[2] General and administrative personnel costs include employee stock-based compensation expense of $48,528 and $122,655 for the three months ended June 30, 2026 and 2025, respectively, and $100,915 and $245,310 for the six months ended June 30, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC.
[3] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
[4] Other income, net consists of interest and dividend income, realized and unrealized loss on our digital asset, and other miscellaneous income.